Dogwood Therapeutics financials
$1.35−0.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$14.1M | -$5.1M | -$3.8M | -$15.8M | -$3.9M | -$4.4M | -$7.5M |
| Net income | -$11.5M | -$5.0M | -$3.8M | -$15.7M | -$3.8M | -$12.2M | -$8.2M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.34 | $-0.15 | $-0.26 | $-8.20 | $-1.99 | $-8.45 | $-6.27 |
| EBITDA | -$4.9M | -$5.1M | -$3.8M | -$15.8M | -$3.9M | -$4.4M | -$7.5M |
| Operating cash flow | -$3.6M | -$4.6M | -$3.6M | -$3.3M | -$4.0M | -$4.7M | -$6.1M |
| Free cash flow | -$3.6M | -$4.6M | -$3.6M | -$3.3M | -$4.0M | -$4.7M | -$6.1M |
| Diluted shares | 34.1M | 33.5M | 14.6M | 1.9M | 1.9M | 1.4M | 1.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.6M | $13.2M | $6.5M | $10.1M | $13.4M | $17.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $80.5M | $95.2M | $90.2M | $92.0M | $96.7M | $97.0M |
| Total liabilities | $12.1M | $14.6M | $15.3M | $14.6M | $14.2M | $14.2M |
| Shareholders' equity | $68.4M | $80.6M | $74.9M | $7.3M | $6.9M | $7.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology